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BACE1 inhibitors by harnessing diverse building
blocks prepared using a unified synthetic approach
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TheQ3 structural diversity of β-site amyloid precursor protein
cleaving enzyme 1 (BACE1) inhibitors was expanded by
harnessing diverse building blocks that had been prepared
via a unified lead-oriented synthetic approach.
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The structural diversity of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors was ex-
panded by harnessing diverse building blocks that had been prepared via a unified lead-oriented synthetic
approach. It was shown that the lipophilic cyclohexylmethyl group within a known series of BACE1 inhibi-






The exploration of chemical space, whilst controlling molecu-
lar properties at each stage of discovery, is an intrinsic chal-
lenge in medicinal chemistry.1 Historically, chemical space
has been explored unevenly and unsystematically,2 which has
limited the scaffold diversity of exemplified medicinal chem-
istry space.3 Furthermore, discovery practices have driven me-
dicinal chemists away from optimal property space, and have
increased the focus on flatter and more lipophilic com-
pounds.4 Molecular weight (MW), lipophilicity and molecular
complexity tend to increase during lead optimisation.5 The
challenge of controlling molecular properties in CNS discov-
ery programmes is further heightened by the need to cross
the blood–brain barrier.6 To assist discovery, a multi-
parameter optimisation (MPO) system for scoring CNS drug-
likeness7 has been developed that integrates scores for six key
molecular properties.‡
Previously, we adapted8 the CNS Lead MPO scoring sys-
tem7 to guide the development of a unified synthetic ap-
proach to diverse scaffolds that, on decoration, would pro-
vide high-quality starting points for CNS drug discovery.9
Here, we demonstrate that these building blocks may be
harnessed to expand the structural diversity of inhibitors of
the CNS target BACE1. BACE1 is an aspartic protease that is
responsible for the formation of amyloid β by sequentialcleavage of amyloid precursor protein (APP).10 The amino-
quinoline fragment 1, which interacts with the two catalytic
Asp residues, previously served as a starting point for
fragment-based inhibitor discovery of BACE1 inhibitors.11
Optimisation had initially involved the addition of an amide
chain (to give 2) bearing a lipophilic cyclohexylmethyl group.
Successive addition of an o-tolyl group (to give 3) and a
methyl group (to give 4) resulted, respectively, in ∼900- and
9-fold increases in activity (Fig. 1).Results and discussion
Initially, we investigated the replacement of the lipophilic
cyclohexylmethyl group in the inhibitor 2 with more highly
functionalised substituents. Here, we exploited diverse build-
ing blocks that had been prepared using a unified synthetic
approach developed to yield lead-like scaffolds for CNS drug
discovery.9 We initially prepared analogues of the amino-
quinoline 2 in two steps from the ester11 5 (Table 1). In each
case, the ester 5 was aminolysed12 with the deprotected ana-
logue of the appropriate racemic amine-containing building. Commun., 2019, 00, 1–5 | 1
ew class of BACE1 inhibitors
50
55
2 | Med. Chem. Commun., 2019, 00, 1–5 This journal is © The Royal Society of Chemistry 2019
Table 1 Synthesis and evaluation of potential BACE1 inhibitors
Building block Product (Methodsa) NR1R2 Inhibition at 100 μM IC50 (μM) [pIC50]
6a 2 (A, 98%; B: 83%) >95% 31 [4.51 ± 0.06]
6b 7b (C, D, A, 21%; B, >99%) <10% —
6c 8b (C, D, A, 60%; B, 93%) <10% —
6d 9b (C, D, A, 75%; B, 32%) >95% 55 [4.26 ± 0.01]
6e 10b (D, A, 28%; B, 98%) >95% 29 [4.54 ± 0.02]
6f 11b (C, D, A, 72%; B, >99%) <10% —
6g 12b (E, A, 20%; B, 99%) <10% —
6h 13b (D, A, 31%; B, >99%) <10% —
6i 14b (E, A, 23%; B, >99%) 67% 84 [4.07 ± 0.01]
6j 15 (A, 56%; B, 93%) <10% —
6k 16 (A, 90%; B, 47%) <10% —
6l 17b (A, 37%; B, >99%) <10% —
6m 18b (A, 43%; B, >99%) <10% —
a Methods: A: TBD, toluene, 75 °C; B: TFA, 75 °C; C: NaOMe, MeOH; D: TFA, CH2Cl2; E: H2, Pd/C, MeOH. TBD, triazabicyclodecene; TFA,













































30block 6 (see Fig. 2); TFA-induced deprotection then gave the
corresponding free aminoquinoline.11 For comparison, the
known inhibitor 2 and its analogues 15–18 were also pre-
pared from commercially-available amines.
Inhibition of BACE1 was initially assessed at 100 μM using
a fluorescence-quenching assay13 based on the cleavage of a
peptide substrate bearing a donor and a quencher at its ter-
mini. The dose-dependent activity of compounds that
displayed significant inhibition at 100 μM was subsequently
determined. Three compounds, in which the cyclo-
hexylmethyl group had been replaced, had broadly compara-
ble activity to the parent aminoquinoline 2 (IC50: 31 μM): the
analogue 10 (IC50: 29 μM) in which the secondary amide link-
age had been retained, and the tertiary amides 9 (IC50: 55
μM) and 14 (IC50: 84 μM). The discovery of tertiary amide in-
hibitors was interesting because the secondary amide NH of
2 has been shown to form a key hydrogen bond interaction
with a glycine residue in the BACE1 active site.11 Notably,
simplified analogues of the active compounds were inactive:
for example, the secondary amide 18 (with a tetrahydropyran
replacing the bicyclic ring system of 10) and the tertiary am-
ide 17 (with a 3-benzyl piperidine replacing the benzyl-
substituted bicyclic ring system of 14).
To provide some structural insights into these structure–
activity relationships, the aminoquinoline 2 and both
enantiomers of 10 and 14 were docked onto BACE1 using
GOLD (Fig. 3 and ESI†).14 The structure of BACE1 in complex
with the aminoquinoline fragment 1 (PDB 2OHL) was used
as a starting point for these in silico studies. Since alternative
conformations of Tyr71 have been observed in BACE com-
plexes with different aminoquinoline ligands,11 this residue
was allowed to be flexible.This journal is © The Royal Society of Chemistry 2019
Fig. 2 Building blocks used in this study. The chiral building blocks
were racemic.
Fig. 3 Interaction of inhibitors with BACE1. Panel A: Docked pose of
the aminoquinoline 2 superimposed on the alternative binding modes
determined by X-ray crystallography (magenta and purple; PDB 3RU1).






55Crystallographic studies had previously shown that the
aminoquinoline 2 has two binding modes11 in which its
cyclohexyl substituent occupies either the P1 (magenta) or
the P1′ (purple) pocket (Fig. 3, Panel A). The docked pose of 2
(green) was similar to the binding mode in which the P1
pocket was targeted, with a similar orientation of Tyr71
(cyan) as the reported crystal structure (blue). Both enantio-
mers of 10 and 14 were also docked (see ESI†). For 10, the
binding mode is predicted to be broadly similar to 2, with a
hydrogen bond maintained between Gly230 and the second-
ary amide NH in the ligand (Panel B). The tertiary amides 9
and 14 lack the capacity to hydrogen bond with Gly230; how-
ever, the benzyl substituent of both enantiomers of 14 is pre-
dicted to bind in the same pocket as the cyclohexyl group of
2 (Panel C).
By analogy with the parent inhibitor 2 (Fig. 1), we investi-
gated the addition of an o-tolyl group and/or a methyl groupMed. Chem. Commun., 2019, 00, 1–5 | 3
Table 2 Synthesis and evaluation of BACE1 inhibitors
Substrate Building block Product Method (yield) pIC50 IC50 (μM)
NR1R2 R3 R4
19 6e 22 H Me D, A, B (43%b) 4.48 ± 0.08 34
20 6e 23 o-Tolyl H D, A, B (60%) 7.11 ± 0.07 0.12
21 6e 24 o-Tolyl Me D, A, B (37%b) 7.51 ± 0.06 0.031
19 6d 25 H Me C, D, A, B (29%b) 5.43 ± 0.02 3.7
20 6d 26 o-Tolyl H C, D, A, B (7%) 5.21 ± 0.06 6.1
21 6d 27 o-Tolyl Me C, D, A, B (16%b) 5.29 ± 0.06 5.1
19 6i 28 H Me E, A, B (18%b) 4.47 ± 0.03 34
20 6i 29 o-Tolyl H E, A, B (39%) 5.50 ± 0.03 3.2
21 6i 30 o-Tolyl Me E, A, B (15%b) 5.57 ± 0.03 2.7
aQ4 Methods: A: TBD, toluene, 75 °C; B: TFA, 75 °C; C: NaOMe, MeOH; D: TFA, CH2Cl2; E: H2, Pd/C, MeOH.
b The use of two racemic reactants
resulted in a 50 : 50 mixture of diastereomeric products. TBD, triazabicyclodecene; TFA, trifluoroacetic acid.
Fig. 4 Complexes of 2-amino-6-o-tolylquinoline inhibitors with
BACE1 with Tyr71 highlighted (cyan). Panel A: Docked pose of a
representative stereoisomer of the ligand 24 [with 2R configuration in
linker and (4aS,8aS)-configured building block] Panel B: co-crystal struc-
ture of 3-(2-amino-6-o-tolylquinolin-3-yl)-N-cyclohexylpropanamide

























55to the compounds 9, 10 and 14 (Table 2). In each case,
aminolysis of the appropriate ester (19, 20 or 21) was
followed TFA-induced deprotection; compounds prepared
from the chiral esters 19 and 21 were obtained as 50 : 50 mix-
tures of racemic diastereomers. The dose-dependent activity
of the resulting nine products was determined.
As with the secondary amide 2, the addition of an o-tolyl
group to 10 (IC50: 29 μM) to give 23 (IC50: 120 nM) resulted
in a dramatic (∼240-fold) improvement in activity. Further-
more, the subsequent addition of a methyl group to 23 (to
give 24; IC50: 31 nM) resulted in a further ∼4-fold improve-
ment in potency. The CNS drug-likeness scores7 of these two
compounds (3.47 for 23 and 3.00 for 24) were broadly compa-
rable with their cyclohexylmethyl analogues (3.20 for 3 and
3.10 for 4). It is therefore possible to replace the cyclo-
hexylmethyl substituent with a less lipophilic group (Δclog P
for each pair: ∼2.1) whilst maintaining both potency and
CNS drug-likeness.
The inhibitor 24, in which both an o-tolyl group and a
methyl group have been incorporated, was docked onto
BACE1 (see ESI† for all stereoisomers). The structure of
BACE1 in complex with the aminoquinoline fragment 1 (PDB
2OHL) was used as a starting point, with alternative confor-
mations of Tyr71 (cyan) allowed. The docked poses were sub-
stantially different to those of its unsubstituted analogue 10
(compare Fig. 4, Panel A and ESI† with Fig. 3, Panel B): the
P1′ pocket was now predicted to be targeted and the Tyr71
had a different orientation and formed a hydrogen bond with























in complex with BACE1 (PDB 3RTN), the cyclohexyl substitu-
ent also targeted the P1′ pocket and Tyr71 had a similar ori-
entation (Fig. 4, Panel B).
With the tertiary amides 9 (IC50: 55 μM) and 14 (IC50: 84
μM), the addition of an o-tolyl group had a much less dra-
matic effect: ∼8-fold (to give 26; IC50: 6.1 μM) and ∼14-fold
(to give 29; IC50: 3.2 μM) improvements in activity respec-
tively were observed. In addition, the subsequent addition of
a methyl groups to 26 and 29 (to give 27 and 30) resulted in
only modest improvements in activity.
Conclusion
We have demonstrated that structurally-diverse, sp3-rich
building blocks that were prepared using a unified lead-
oriented approach can significant enrich structure–activity
relationships. In particular, we showed that the cyclo-
hexylmethyl group in a series of known BACE1 inhibitors
could be replaced productively with alternative structurally-
diverse ring systems. Notably, the incorporation of simplified
analogues of these alternative ring systems was not produc-
tive, and did not yield active BACE1 inhibitors. The availabil-
ity of diverse building blocks via a lead-oriented synthetic ap-
proach therefore enabled the replacement of a lipophilic
substituent with maintenance of both potency and CNS drug-
likeness. The exploitation of diverse building blocks with
controlled molecular properties within drug discovery
programmes thus may significantly expand opportunities in
lead discovery and optimisation.
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